AEYE Health, a leader in AI-powered retinal diagnostics, announces its strategic partnership with Ford Medical, a healthcare distributor dedicated to supporting non-acute care providers. The collaboration will bring AEYE’s fully autonomous diabetic eye exam screening solutions to pharmacies and non-acute centers nationwide – making early detection of diabetic retinopathy easier, on-the-spot and more widely accessible for patients.
With diabetes rates on the rise, pharmacies have become vital access points for retinal screening. Diabetic retinopathy is the leading cause of blindness among the working-age population – yet it is preventable in the vast majority of cases. Unfortunately, most diabetic patients are not screened annually, as recommended by clinical guidelines. AEYE-DS, AEYE Health’s AI-driven technology, enables point-of-care screening for patients who may not regularly see an eye specialist – enhancing care outreach, expanding pharmacy services, and creating new revenue opportunities. AEYE-DS is the first and only FDA-cleared AI solution compatible with a portable camera, making retinal screening truly feasible in a pharmacy setting.
Through this partnership, Ford Medical will distribute AEYE Health’s FDA-cleared AI screening solutions, enabling pharmacies and non-acute centers to offer an in-house, non-invasive eye exam that delivers immediate diagnostic results without the need for a specialist. The solution closes care gaps and is fully reimbursable under an existing CPT code, empowering point-of-care providers to prevent vision loss.
Also Read: Asepha Raises $4M in 5x Oversubscribed Seed Round for AI Pharmacy
“We’re excited to collaborate with Ford Medical to bring AEYE-DS into pharmacies and non-acute centers – a strategic step toward making diabetic eye exams more accessible than ever,” said Zack Dvey-Aharon, Ph.D., CEO & Co-Founder of AEYE Health. “By integrating fully autonomous AI into everyday care settings, we’re making it much easier to detect disease early and prevent blindness for millions at risk.”
“This partnership with AEYE Health represents a major step forward in making AI-driven diagnostics more accessible,” said Scott Greenberg, Vice President of Sales at Ford Medical. “We’re giving non-acute providers the ability to deliver real clinical value through early detection – keeping patients healthier and helping providers grow their impact and their business.”
AEYE Health and Ford Medical to Exhibit at ThoughtSpot 2025
AEYE Health and Ford Medical will be showcasing AEYE-DS, the first FDA-cleared, fully autonomous AI diagnostic system for portable diabetic eye screening, at ThoughtSpot 2025, taking place July 16–19, 2025, at the MGM Grand in Las Vegas, NV. Hosted by Good Neighbor Pharmacy (GNP) and Cencora, ThoughtSpot is the premier annual event for independent pharmacies, attracting pharmacy owners, clinicians, managers and industry leaders focused on innovative solutions that drive growth and boost clinical efficiency.
As part of the event’s mock pharmacy experience, attendees will have the opportunity to see firsthand how AEYE-DS enables on-the-spot diabetic eye exams with no dilation and delivers accurate AI results in just one minute. The solution requires just one image per eye, using either a portable or tabletop fundus camera, making it a seamless addition to pharmacy workflows and other non-acute care settings. This innovative technology helps pharmacies expand their service offerings while enhancing patient care.
Source: PRNewswire
